

**Clinical Trials - Company Evaluation Report, 2025**

Market Report | 2025-08-01 | 172 pages | MarketsandMarkets

**AVAILABLE LICENSES:**

- Single User \$2650.00
- Corporate License \$4250.00

**Report description:**

The clinical trial services Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for clinical trial services. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and emerging trends shaping the industry. MarketsandMarkets 360 Quadrants evaluated over 100 companies, of which the Top 19 EVA Films Companies were categorized and recognized as the quadrant leaders.

A clinical trial services is an electronic device that uses the mechanical resonance of a piezoelectric material-based vibrating crystal to generate an electric pulse of a specific frequency. The electrical signal generated by the crystal oscillator is used to keep track of time in quartz wristwatches, provide a stable clock signal for digital ICs, and stabilize the frequencies of radio transmitters and receivers. The oscillations generated by the crystal can be set or modified to generate the desired frequency signals according to application requirements. For the past few years, major players in the crystal oscillator market have adopted product launches and developments as their key strategies. Companies also adopt several other growth strategies, such as collaborations, acquisitions, and partnerships, to increase their market share.

The 360 Quadrant maps the clinical trial services companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the clinical trial services quadrant. The top criteria for product footprint evaluation included by service type (clinical trial management & monitoring services; laboratory services, including analytical testing and bioanalytical testing; patient recruitment & retention services; medical writing services; clinical trial supply & logistic services; safety & pharmacovigilance services; clinical trial data management services such as biostatistics and other data management services; consulting; and other service types) by phase (Phase I, Phase II, Phase III, & Phase IV) by MODALITY (small molecules, biologics, and medical devices & IVD) therapeutic area (oncology, neurology, infectious diseases, cardiovascular system (CVS) disorders, metabolic disorders/endocrinology, immunological disorders, respiratory disorders, psychiatry, dermatology, hematology, ophthalmology, gastrointestinal diseases, genitourinary & women's health, and other therapeutic areas.) by Delivery Model (full-service outsourcing (FSO), functional service providers (FSP), and hybrid models), by STUDY Design (interventional and observational.) and END USER (large pharma-biotech companies, small & mid-sized pharma-biotech companies, CROs, medical device manufacturers, and other end users..)

**Key Players:**

Key players operating in the clinical trial services IQVIA Inc. (US), Thermo Fisher Scientific Inc. (US), Fortrea (US), ICON Plc (Ireland), Syneos Health (US), Laboratory Corporation of America Holdings (US), Medpace (US), WuXi AppTec (China), Frontage

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Labs (US), Pharmaron (US), Tigermmed (China), SGS Societe Generale De Surveillance SA. (Switzerland), Eurofins Scientific (Luxembourg), Linical (Japan), and Parexel International Corporation (US), among others.

IQVIA Inc.

IQVIA is a major player in the clinical trials market, leveraging its advanced data analytics and global reach to drive drug development. The company's Connected Intelligence platform is instrumental in optimizing trial protocols and patient selection. Through its strategic partnerships with pharmaceutical companies and clinical technology vendors, IQVIA enhances industry-wide adoption and efficiency in clinical timelines.

ICON Plc

ICON Plc, headquartered in Ireland, offers a comprehensive range of clinical development services for pharmaceuticals, biotechnology, and medical devices. The integration of AI into ICON's service offerings improves data management and patient recruitment processes, reinforcing its market position. The company's commitment to innovation ensures its adaptability to evolving market dynamics.

Thermo Fisher Scientific Inc.

Thermo Fisher has strengthened its clinical research services significantly through its acquisition of PPD. This strategic move has expanded its market footprint, making it a leading provider for pharmaceutical and biotech companies globally. The company is notable for its extensive service portfolio and focus on geographic expansion to support diverse clientele.

## **Table of Contents:**

|         |   |    |
|---------|---|----|
| 1       | INTRODUCTION  | 13 |
| 1.1     | MARKET DEFINITION   | 13 |
| 1.2     | STAKEHOLDERS  | 13 |
| 2       | EXECUTIVE SUMMARY   | 14 |
| 3       | MARKET OVERVIEW   | 19 |
| 3.1     | INTRODUCTION  | 19 |
| 3.2     | MARKET DYNAMICS   | 19 |
| 3.2.1   | DRIVERS   | 20 |
| 3.2.1.1 | Increasing focus on patient-centric trials (DCTs)   | 20 |
| 3.2.1.2 | Increasing clinical trials for precision/personalized medicines supporting growth in clinical trial outsourcing | 21 |
| 3.2.1.3 | Rising R&D investments and patent cliff pressure driving growth in outsourcing clinical trial activities        | 22 |
| 3.2.1.4 | Service flexibility offered by CROs for clinical development (FSP, FSO, Hybrid)                                 | 23 |
| 3.2.1.5 | Technological integrations  | 24 |
| 3.2.2   | OPPORTUNITIES   | 24 |
| 3.2.2.1 | Increased focus on pediatric clinical trials  | 24 |
| 3.2.2.2 | Increasing regulatory requirements for increasing diversity in clinical trials                                  | 25 |
| 3.2.2.3 | Growing role of real-world evidence in drug approvals   | 26 |
| 3.2.2.4 | Expanding drug modalities (such as CGT, Tissue Engineering, Bispecific Abs) in clinical trials                  | 27 |
| 3.2.3   | CHALLENGES  | 28 |
| 3.2.3.1 | Cybersecurity or intellectual property concerns   | 28 |
| 3.2.3.2 | Challenge of patient retention  | 29 |
| 3.2.3.3 | Growing market competition  | 29 |
| 3.3     | MARKET TRENDS   | 30 |
| 3.3.1   | IN SILICO CLINICAL TRIALS   | 30 |
| 3.4     | TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS  | 30 |
| 3.5     | VALUE CHAIN ANALYSIS  | 31 |
| 3.6     | ECOSYSTEM ANALYSIS  | 33 |
| 3.7     | TECHNOLOGY ANALYSIS   | 35 |
| 3.7.1   | KEY TECHNOLOGIES  | 35 |

|   |
|---|
| 3.7.1.1 Clinical trial management system (CTMS) 35            |
| 3.7.1.2 Electronic data capture (EDC) systems 36              |
| 3.7.1.3 Randomization and trial supply management (RTSM) 36   |
| ?   |
| 3.7.2 COMPLEMENTARY TECHNOLOGIES 37                           |
| 3.7.2.1 Telemedicine and wearable devices 37                  |
| 3.7.2.2 AI and ML integration 37                              |
| 3.8 KEY CONFERENCES AND EVENTS, 2025-2026 38                  |
| 3.9 PORTER'S FIVE FORCES ANALYSIS 39                          |
| 3.9.1 THREAT OF NEW ENTRANTS 40                               |
| 3.9.2 THREAT OF SUBSTITUTES 41                                |
| 3.9.3 BARGAINING POWER OF SUPPLIERS 41                        |
| 3.9.4 BARGAINING POWER OF BUYERS 41                           |
| 3.9.5 INTENSITY OF COMPETITIVE RIVALRY 41                     |
| 3.10 IMPACT OF AI/GEN AI ON CLINICAL TRIAL SERVICES MARKET 42 |
| 3.10.1 INTRODUCTION 42  |
| 3.10.2 MARKET POTENTIAL FOR CLINICAL TRIALS 42                |
| 3.10.3 AI USE CASES 43  |
| 3.10.4 KEY COMPANIES IMPLEMENTING AI 44                       |
| 3.10.5 FUTURE OF GENERATIVE AI IN CLINICAL TRIAL ECOSYSTEM 44 |
| 4 COMPETITIVE LANDSCAPE 45                                    |
| 4.1 OVERVIEW 45   |
| 4.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 45                     |
| 4.3 REVENUE ANALYSIS 48                                       |
| 4.4 MARKET SHARE ANALYSIS, 2024 48                            |
| 4.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 51           |
| 4.5.1 STARS 51  |
| 4.5.2 EMERGING LEADERS 51                                     |
| 4.5.3 PERVERSIVE PLAYERS 51                                   |
| 4.5.4 PARTICIPANTS 51   |
| 4.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 52                 |
| 4.5.5.1 Company footprint 52                                  |
| 4.5.5.2 Region footprint 54                                   |
| 4.5.5.3 Service type footprint 55                             |
| 4.5.5.4 Phase footprint 56                                    |
| 4.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 57         |
| 4.6.1 PROGRESSIVE COMPANIES 57                                |
| 4.6.2 RESPONSIVE COMPANIES 57                                 |
| 4.6.3 DYNAMIC COMPANIES 57                                    |
| 4.6.4 STARTING BLOCKS 58                                      |
| 4.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 59        |
| 4.6.5.1 Detailed list of key startups/SMEs 59                 |
| 4.6.5.2 Competitive benchmarking of startups/SMEs 60          |
| 4.7 COMPANY VALUATION AND FINANCIAL METRICS 61                |
| 4.8 BRAND/SERVICE COMPARISON 62                               |
| 4.9 COMPETITIVE SCENARIO 63                                   |
| 4.9.1 SERVICE LAUNCHES 63                                     |

|  |     |
|--|-----|
| 4.9.2 DEALS                                  | 64  |
| 4.9.3 EXPANSIONS                             | 65  |
| 5 COMPANY PROFILES                           | 66  |
| 5.1 KEY PLAYERS                              | 66  |
| 5.1.1 IQVIA INC.                             | 66  |
| 5.1.1.1 Business overview                    | 66  |
| 5.1.1.2 Services offered                     | 67  |
| 5.1.1.3 Recent developments                  | 69  |
| 5.1.1.3.1 Service launches                   | 69  |
| 5.1.1.3.2 Deals                              | 69  |
| 5.1.1.3.3 Expansions                         | 71  |
| 5.1.1.4 MnM view                             | 72  |
| 5.1.1.4.1 Right to win                       | 72  |
| 5.1.1.4.2 Strategic choices                  | 72  |
| 5.1.1.4.3 Weaknesses and competitive threats | 72  |
| 5.1.2 ICON PLC                               | 73  |
| 5.1.2.1 Business overview                    | 73  |
| 5.1.2.2 Services offered                     | 74  |
| 5.1.2.3 Recent developments                  | 80  |
| 5.1.2.3.1 Service launches                   | 80  |
| 5.1.2.3.2 Deals                              | 81  |
| 5.1.2.4 MnM view                             | 82  |
| 5.1.2.4.1 Right to win                       | 82  |
| 5.1.2.4.2 Strategic choices                  | 82  |
| 5.1.2.4.3 Weaknesses and competitive threats | 82  |
| 5.1.3 THERMO FISHER SCIENTIFIC INC.          | 83  |
| 5.1.3.1 Business overview                    | 83  |
| 5.1.3.2 Services offered                     | 84  |
| 5.1.3.3 Recent developments                  | 89  |
| 5.1.3.3.1 Service launches                   | 89  |
| 5.1.3.3.2 Deals                              | 90  |
| 5.1.3.3.3 Expansions                         | 92  |
| 5.1.3.4 MnM view                             | 93  |
| 5.1.3.4.1 Right to win                       | 93  |
| 5.1.3.4.2 Strategic choices                  | 93  |
| 5.1.3.4.3 Weaknesses and competitive threats | 93  |
| 5.1.4 FORTREA                                | 94  |
| 5.1.4.1 Business overview                    | 94  |
| 5.1.4.2 Services offered                     | 95  |
| 5.1.4.3 Recent developments                  | 99  |
| 5.1.4.3.1 Service launches                   | 99  |
| 5.1.4.3.2 Deals                              | 99  |
| 5.1.4.3.3 Expansions                         | 100 |
| 5.1.4.4 MnM view                             | 100 |
| 5.1.4.4.1 Right to win                       | 100 |
| 5.1.4.4.2 Strategic choices                  | 100 |
| 5.1.4.4.3 Weaknesses and competitive threats | 100 |

|  |     |
|--|-----|
| 5.1.5.0 SYNEOS HEALTH                              | 101 |
| 5.1.5.1.0 Business overview                        | 101 |
| 5.1.5.2.0 Services offered                         | 102 |
| 5.1.5.3.0 Recent developments                      | 103 |
| 5.1.5.3.1.0 Service launches                       | 103 |
| 5.1.5.3.2.0 Deals                                  | 103 |
| 5.1.5.4.0 MnM view                                 | 106 |
| 5.1.5.4.1.0 Right to win                           | 106 |
| 5.1.5.4.2.0 Strategic choices                      | 106 |
| 5.1.5.4.3.0 Weaknesses and competitive threats     | 106 |
| 5.1.6.0 LABORATORY CORPORATION OF AMERICA HOLDINGS | 107 |
| 5.1.6.1.0 Business overview                        | 107 |
| 5.1.6.2.0 Services offered                         | 109 |
| 5.1.6.3.0 Recent developments                      | 109 |
| 5.1.6.3.1.0 Service launches                       | 109 |
| 5.1.6.3.2.0 Deals                                  | 110 |
| 5.1.6.3.3.0 Expansions                             | 111 |
| 5.1.6.4.0 MnM view                                 | 112 |
| 5.1.6.4.1.0 Right to win                           | 112 |
| 5.1.6.4.2.0 Strategic choices                      | 112 |
| 5.1.6.4.3.0 Weaknesses and competitive threats     | 112 |
| 5.1.7.0 MEDPACE                                    | 113 |
| 5.1.7.1.0 Business overview                        | 113 |
| 5.1.7.2.0 Services offered                         | 114 |
| 5.1.8.0 WUXI APPTEC                                | 117 |
| 5.1.8.1.0 Business overview                        | 117 |
| 5.1.8.2.0 Services offered                         | 118 |
| 5.1.8.3.0 Recent developments                      | 121 |
| 5.1.8.3.1.0 Deals                                  | 121 |
| 5.1.9.0 FRONTAGE LABS                              | 122 |
| 5.1.9.1.0 Business overview                        | 122 |
| 5.1.9.2.0 Services offered                         | 123 |
| 5.1.9.3.0 Recent developments                      | 124 |
| 5.1.9.3.1.0 Deals                                  | 124 |
| 5.1.9.3.2.0 Expansions                             | 125 |
| 5.1.10.0 PHARMARON                                 | 126 |
| 5.1.10.1.0 Business overview                       | 126 |
| 5.1.10.2.0 Services offered                        | 128 |
| 5.1.11.0 TIGERMED                                  | 129 |
| 5.1.11.1.0 Business overview                       | 129 |
| 5.1.11.2.0 Services offered                        | 130 |
| 5.1.11.3.0 Recent developments                     | 132 |
| 5.1.11.3.1.0 Service approvals                     | 132 |
| 5.1.11.3.2.0 Deals                                 | 133 |
| 5.1.12.0 SGS SOCIETE GENERALE DE SURVEILLANCE SA   | 134 |
| 5.1.12.1.0 Business overview                       | 134 |
| 5.1.12.2.0 Services offered                        | 135 |

|  |     |
|--|-----|
| 5.1.13 EUROFINS SCIENTIFIC                 | 136 |
| 5.1.13.1 Business overview                 | 136 |
| 5.1.13.2 Services offered                  | 138 |
| 5.1.14 CLINICAL                            | 139 |
| 5.1.14.1 Business overview                 | 139 |
| 5.1.14.2 Services offered                  | 141 |
| 5.1.14.3 Recent developments               | 141 |
| 5.1.14.3.1 Deals                           | 141 |
| 5.1.14.3.2 Expansions                      | 142 |
| 5.1.15 PAREXEL INTERNATIONAL CORPORATION   | 143 |
| 5.1.15.1 Business overview                 | 143 |
| 5.1.15.2 Services offered                  | 144 |
| 5.1.15.3 Recent developments               | 145 |
| 5.1.15.3.1 Service launches                | 145 |
| 5.1.15.3.2 Deals                           | 145 |
| 5.1.15.3.3 Expansions                      | 147 |
| 5.2 OTHER PLAYERS                          | 148 |
| 5.2.1 WORLDWIDE CLINICAL TRIALS            | 148 |
| 5.2.2 PROPHARMA                            | 150 |
| 5.2.3 NOVOTECH                             | 151 |
| 5.2.4 PSI                                  | 154 |
| 5.2.5 ALLUCENT                             | 155 |
| 5.2.6 PREMIER RESEARCH                     | 156 |
| 5.2.7 CAIDYA                               | 157 |
| 5.2.8 ERGOMED GROUP                        | 158 |
| 5.2.9 CLARIO                               | 160 |
| 5.2.10 PRECISION MEDICINE GROUP, LLC.      | 161 |
| 5.2.11 ADVANCED CLINICAL                   | 162 |
| 5.2.12 EPS HOLDINGS, INC.                  | 163 |
| 5.2.13 GUIRES INC. (PEPGRA)                | 164 |
| 5.2.14 KCR S.A.                            | 165 |
| 6 APPENDIX                                 | 166 |
| 6.1 RESEARCH METHODOLOGY                   | 166 |
| 6.1.1 RESEARCH DATA                        | 166 |
| 6.1.1.1 Secondary data                     | 166 |
| 6.1.1.2 Primary data                       | 167 |
| 6.1.2 RESEARCH ASSUMPTIONS                 | 167 |
| 6.1.3 RESEARCH LIMITATIONS                 | 168 |
| 6.2 COMPANY EVALUATION MATRIX: METHODOLOGY | 169 |
| 6.3 AUTHOR DETAILS                         | 172 |

**Clinical Trials - Company Evaluation Report, 2025**

Market Report | 2025-08-01 | 172 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

| Select license | License           | Price     |
|----------------|-------------------|-----------|
|                | Single User       | \$2650.00 |
|                | Corporate License | \$4250.00 |
|                |                   | VAT       |
|                |                   | Total     |

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

|               |                      |                               |   |
|---------------|----------------------|-------------------------------|---|
| Email*        | <input type="text"/> | Phone*                        | <input type="text"/>                    |
| First Name*   | <input type="text"/> | Last Name*                    | <input type="text"/>                    |
| Job title*    | <input type="text"/> |                               |   |
| Company Name* | <input type="text"/> | EU Vat / Tax ID / NIP number* | <input type="text"/>                    |
| Address*      | <input type="text"/> | City*                         | <input type="text"/>                    |
| Zip Code*     | <input type="text"/> | Country*                      | <input type="text"/>                    |
|               |                      | Date                          | <input type="text" value="2026-02-18"/> |
|               |                      | Signature                     | <input type="text"/>                    |

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com